Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies

Kristen B. McCullough, Miriam A. Hobbs, Jithma P. Abeykoon, Prashant Kapoor

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Purpose of Review: The purpose of this review was to evaluate management strategies for common adverse effects of novel therapies in multiple myeloma (MM), including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and a histone deacetylase inhibitor. Recent Findings: There are several adverse effects that occur across multiple classes of antimyeloma drugs, including rash, peripheral neuropathy, infusion reactions, and cardiotoxicity, but most can be managed without complete discontinuation of the agent or abandonment of the class. Additionally, several agents have critically important drug-drug interactions or dose-modification implications in hepatic or renal insufficiency that can be easily overlooked, and exacerbate adverse effects. Summary: As treatment of MM moves from fixed-duration traditional chemotherapy to novel agent-based regimens, commonly administered continuously until disease progression or intolerable toxicities, providers must adopt their management strategies for both acute and long-term adverse effects. Early and frequent monitoring for therapy-related complications, dose adjustments when needed, and timely treatment for toxicities are all important steps toward ensuring longevity of treatment from a limited array of therapeutic options that currently exist for a disease with a relapsing and remitting course.

Original languageEnglish (US)
Pages (from-to)114-124
Number of pages11
JournalCurrent Hematologic Malignancy Reports
Volume13
Issue number2
DOIs
StatePublished - Apr 1 2018

Fingerprint

Multiple Myeloma
Therapeutics
Pharmaceutical Preparations
Hepatic Insufficiency
Proteasome Inhibitors
Histone Deacetylase Inhibitors
Peripheral Nervous System Diseases
Exanthema
Drug Interactions
Renal Insufficiency
Disease Progression
Monoclonal Antibodies
Drug Therapy

Keywords

  • Daratumumab
  • Elotuzumab
  • Immunomodulatory drugs
  • Panobinostat
  • Proteasome inhibitors
  • Toxicities

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies. / McCullough, Kristen B.; Hobbs, Miriam A.; Abeykoon, Jithma P.; Kapoor, Prashant.

In: Current Hematologic Malignancy Reports, Vol. 13, No. 2, 01.04.2018, p. 114-124.

Research output: Contribution to journalReview article

McCullough, Kristen B. ; Hobbs, Miriam A. ; Abeykoon, Jithma P. ; Kapoor, Prashant. / Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies. In: Current Hematologic Malignancy Reports. 2018 ; Vol. 13, No. 2. pp. 114-124.
@article{8abd05bafb8a46a2aba80ed6ff834374,
title = "Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies",
abstract = "Purpose of Review: The purpose of this review was to evaluate management strategies for common adverse effects of novel therapies in multiple myeloma (MM), including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and a histone deacetylase inhibitor. Recent Findings: There are several adverse effects that occur across multiple classes of antimyeloma drugs, including rash, peripheral neuropathy, infusion reactions, and cardiotoxicity, but most can be managed without complete discontinuation of the agent or abandonment of the class. Additionally, several agents have critically important drug-drug interactions or dose-modification implications in hepatic or renal insufficiency that can be easily overlooked, and exacerbate adverse effects. Summary: As treatment of MM moves from fixed-duration traditional chemotherapy to novel agent-based regimens, commonly administered continuously until disease progression or intolerable toxicities, providers must adopt their management strategies for both acute and long-term adverse effects. Early and frequent monitoring for therapy-related complications, dose adjustments when needed, and timely treatment for toxicities are all important steps toward ensuring longevity of treatment from a limited array of therapeutic options that currently exist for a disease with a relapsing and remitting course.",
keywords = "Daratumumab, Elotuzumab, Immunomodulatory drugs, Panobinostat, Proteasome inhibitors, Toxicities",
author = "McCullough, {Kristen B.} and Hobbs, {Miriam A.} and Abeykoon, {Jithma P.} and Prashant Kapoor",
year = "2018",
month = "4",
day = "1",
doi = "10.1007/s11899-018-0443-0",
language = "English (US)",
volume = "13",
pages = "114--124",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "2",

}

TY - JOUR

T1 - Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies

AU - McCullough, Kristen B.

AU - Hobbs, Miriam A.

AU - Abeykoon, Jithma P.

AU - Kapoor, Prashant

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Purpose of Review: The purpose of this review was to evaluate management strategies for common adverse effects of novel therapies in multiple myeloma (MM), including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and a histone deacetylase inhibitor. Recent Findings: There are several adverse effects that occur across multiple classes of antimyeloma drugs, including rash, peripheral neuropathy, infusion reactions, and cardiotoxicity, but most can be managed without complete discontinuation of the agent or abandonment of the class. Additionally, several agents have critically important drug-drug interactions or dose-modification implications in hepatic or renal insufficiency that can be easily overlooked, and exacerbate adverse effects. Summary: As treatment of MM moves from fixed-duration traditional chemotherapy to novel agent-based regimens, commonly administered continuously until disease progression or intolerable toxicities, providers must adopt their management strategies for both acute and long-term adverse effects. Early and frequent monitoring for therapy-related complications, dose adjustments when needed, and timely treatment for toxicities are all important steps toward ensuring longevity of treatment from a limited array of therapeutic options that currently exist for a disease with a relapsing and remitting course.

AB - Purpose of Review: The purpose of this review was to evaluate management strategies for common adverse effects of novel therapies in multiple myeloma (MM), including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and a histone deacetylase inhibitor. Recent Findings: There are several adverse effects that occur across multiple classes of antimyeloma drugs, including rash, peripheral neuropathy, infusion reactions, and cardiotoxicity, but most can be managed without complete discontinuation of the agent or abandonment of the class. Additionally, several agents have critically important drug-drug interactions or dose-modification implications in hepatic or renal insufficiency that can be easily overlooked, and exacerbate adverse effects. Summary: As treatment of MM moves from fixed-duration traditional chemotherapy to novel agent-based regimens, commonly administered continuously until disease progression or intolerable toxicities, providers must adopt their management strategies for both acute and long-term adverse effects. Early and frequent monitoring for therapy-related complications, dose adjustments when needed, and timely treatment for toxicities are all important steps toward ensuring longevity of treatment from a limited array of therapeutic options that currently exist for a disease with a relapsing and remitting course.

KW - Daratumumab

KW - Elotuzumab

KW - Immunomodulatory drugs

KW - Panobinostat

KW - Proteasome inhibitors

KW - Toxicities

UR - http://www.scopus.com/inward/record.url?scp=85042072836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042072836&partnerID=8YFLogxK

U2 - 10.1007/s11899-018-0443-0

DO - 10.1007/s11899-018-0443-0

M3 - Review article

C2 - 29450683

AN - SCOPUS:85042072836

VL - 13

SP - 114

EP - 124

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 2

ER -